- Crystalline methyl carbamate compound
-
The invention relates to a crystalline methyl carbamate compound, namely a crystal form of N-[(2S)-1-[(2S)-2-{4-[7-(4-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutyryl]pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)-2H-1,3-benzodioxan-4-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxybutan-2-yl]methyl carbamate dihydrochloride, a pharmaceutical composition containing the crystal form, anda use of the crystal form in preparation of drugs in treatment of hepatitis C virus.
- -
-
Paragraph 0041; 0042;0043; 0044; 0045
(2018/11/03)
-
- NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
-
The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
- -
-
-